
LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE, Sep 17, 2020 - (ACN Newswire) - Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic...
Read more: Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development